Cytori Therapeutics, Inc. is a biotechnology company developing autologous cell therapies from adipose connective tissue designed to treat a variety of medical conditions. Since 2001, the company has leveraged its exploration of the massive treatment potential of adult adipose-derived stem and regenerative cells to position itself as a global leader in the emerging field of regenerative medicine. By utilizing a patient’s own adipose tissue, Cytori eliminates the necessity for offsite cell growth operations while effectively minimizing common transplant risks, including autoimmune rejection.

The company’s current cell therapy pipeline includes three drug candidates in six unique indications across two countries and the European Union. Cytori’s leading candidate, ECCS-50, is currently approved in the United States and Europe to begin a phase III clinical trial for the treatment of scleroderma hand dysfunction.

According to the National Institute of Health, scleroderma is a group of diseases that affect connective tissue in the body, potentially causing swelling or pain in the muscles and joints. Despite affecting as many as 100,000 people in the United States, there is currently no drug that has been clearly proven to stop, or reverse, the disease’s key symptoms. For Cytori, this unmet need should clear the way for favorable results upon the eventual commercialization of ECCS-50.

From a financial standpoint, Cytori took major steps in the first quarter of 2015 toward continued development and testing of its promising product pipeline. The company’s operating cash burn was reduced by over 44 percent in the period and overall contract revenue rose by 350 percent, as compared to the first quarter of 2014, providing prospective investors with a preview of the Cytori’s growth potential moving forward.

“We accomplished the key objectives we hoped to achieve over the past four quarters and are off to a good start in 2015,” Dr. Marc H. Hendrick, president and chief executive officer of Cytori, stated in a news release. “Now the lion’s share of our corporate focus and energy will go into trial enrollment and strategically managing our clinical pipeline.”

In June, the company made progress toward this objective through the completion of enrollment for its impending phase IIb clinical trial, which will study the safety, feasibility and dosing intraarticular administration of Cytori’s ECCO-50 cellular therapeutic in patients with knee osteoarthritis. Look for the company to build on this progress in the months to come as it prepares for its pivotal phase III trial of ECCS-50.

For more information, visit www.cytori.com

Galaxy Gaming, Inc. (OTCQB: GLXZ) is a gaming company that’s engaged in the business of designing, manufacturing and acquiring proprietary casino table games and associated technology, platforms and systems for the global gaming industry. The company’s current base of products includes over 4,000 gaming tables located in more than 500 casinos, making it the world’s largest independent provider of proprietary table games.

Leveraging a formidable portfolio of intellectual property related to its unique game concepts, Galaxy markets its products to land-based, riverboat and cruise ship gaming establishments, as well as internet gaming companies, in order to enhance their gaming floor operations and improve profitability, productivity and security.

In the first quarter of 2015, Galaxy achieved a 14 percent year-over-year increase in total revenue, recording more than $2.5 million for the period. Despite a 15 percent year-over-year decrease in adjusted EBITDA for the quarter, Galaxy’s management team is optimistic about the strength of the company’s market position moving forward.

“The first quarter has historically been the period we see the lowest revenue growth rates of the year,” Gary A. Vecchiarelli, chief financial officer of Galaxy, stated in a news release. “While several factors contributed to our first decrease of recurring revenues in the last three years, we are not concerned it will have impact on future quarters. Our adjusted EBIDTA and fundamentals of the business remain strong and we expect a strong 2015.”

In April, Galaxy took a significant step toward continued growth when it achieved approval from the Kansas Racing and Gaming Commission to conduct business directly with state-owned casinos. This should provide the company with a platform for considerable industry growth in the months to come. According to a report by the Kansas Lottery, Kansas’s three state-owned casinos are expected to account for more than $336 million in gaming revenue during 2015.

“This approval now opens the door for us to conduct business directly with Kansas casino operators,” stated Robert Saucier, chief executive officer of Galaxy. “We now intend to aggressively increase our presence there and expand our already established great partnerships with many of the prosperous casino resorts located in that market.”

Under the leadership of a proven management team, Galaxy is in a strong position to increase its industry presence within the thriving casino industry in the years to come. According to a report by Statista, global casino gaming revenue has experienced consistent growth since 2009, climbing to forecast revenue of more than $182 billion in 2015. For prospective investors, Galaxy’s strategic position within one of the most consistently performing sectors of the global economy could translate into sustainable returns moving forward.

For more information, visit www.galaxygaming.com

Organovo Holdings, Inc. (NYSE MKT: ONVO) is an early commercial stage company focusing on the development and commercialization of functional human tissues for use in drug discovery and medical research. Utilizing its proprietary three-dimensional bioprinting technology, the company enables reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. Organovo’s exVive3D™ product portfolio includes a recently launched 3D human liver tissue for use in toxicology and preclinical drug testing. The company plans to expand upon its existing product portfolio in the latter half of 2016 through the launch of its exVive3D human kidney tissue.

Since launching its 3D human liver tissue on April 1, 2014, the company has made significant strides toward increasing its market share within the $50 billion research and development sector of the pharmaceutical industry. Earlier this month, Organovo reported that it had already recording total contract bookings for its innovative product amounting to approximately $1.94 million, including $0.29 million in existing revenue. Among these orders, the company secured partnerships with top 25 global pharmaceutical companies, as well as additional public pharmaceutical companies of all sizes in the United States, Europe and Asia.

“Response to the exVive3D human liver tissue has been strong, and in line with our expectations,” Keith Murphy, chief executive officer of Organovo, stated in a news release. “We continue to expect this tissue to grow into the tens of millions in annual revenue, and that it has $100M+ revenue potential.”

For Organovo, fiscal year 2015 was filled with milestones that should provide the company with a strong platform to realize sustainable returns moving forward. The release of the exVive3D human liver tissue set the stage for a host of industry recognition – including being named among the ‘Top 10 Innovations of 2014’ by The Scientist magazine and ‘The World’s Top 10 Most Innovative Companies of 2015’ by Fast Company magazine. Additionally, Organovo diversified its market potential through a partnership with L’Oreal USA to develop 3D printed skin tissues for product evaluation, marking the company’s first foray into the beauty industry.

The company’s current momentum following the successful release of its initial product could be a promising indication of Organovo’s future growth potential. For prospective shareholders, the recent commercialization of its exVive3D human liver tissue, as well as the continued development of its human kidney tissue product, makes Organovo an exciting investment opportunity to put on radar.

For more information, visit www.organovo.com

Cleartronic is wrapping up the first half of 2015 with a flurry of activity. Earlier this month the company’s ReadyOp Communications subsidiary launched a project with a major retail corporation, and followed-up the news that its VoiceInterop, Inc. subsidiary had signed a deal with an airport in Alberta, Canada.

As a technology holding company, Cleartronic is amassing a portfolio of subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises. Cleartronic is carving its niche in a broader industry occupied by wireless communications companies like Fusion Telecommunications International, Inc. (NASDAQ:FSNN) and Ubiquiti Networks, Inc. (NASDAQ:UBNT), differentiating itself by offering unique interoperable communications solutions.

Through a license agreement with Collabria LLC, Cleartronic has the right to market the command, control and communication platform, ReadyOp™. The web-based application integrates multiple databases and a robust communications platform to enable fast, efficient access to information and for communication with multiple persons, groups and agencies.

While ReadyOp is typically used by numerous federal, state and local government agencies, Cleartronic is expanding its applications to a variety of industries. ReadyOp Communications recently began work on a multi-year with a major retail corporation based in Arkansas. The project will integrate the ReadyOp platform for the planning, monitoring and reporting of the work done for each individual store location.

“We are pleased to be an integral part of this project as it shows the versatility and flexibility of the ReadyOp platform. While our main focus has been with first responders and government agencies, this project illustrates how ReadyOp can be used in many different industries. This will be our first entry into the retail sector and our plans are to use this project as a model for other opportunities in the retail sector,” ReadyOp Communications President Marc Moore stated in the news release.

Effective communication is a benchmark of Cleartronic’s operations, and to that accord, VoiceInterop recently signed an agreement with the Edmonton Airports in Alberta, Canada, to provide mission critical system for emergency response at Edmonton International Airport.

VoiceInterop’s emergency communication solution, the “VoiceInterop Crash Phone,” combines VoiceInterop’s engineered software with modern, commercial off-the-shelf products that specifically address the needs of commercial aviation airports. Per the agreement, VoiceInterop has engineered and will install, test and provide support for a customized state-of-the-art crash phone solution – the most vital piece of an airport’s communications system – that provides instant voice communications from the air traffic control tower to the airport rescue firefighting station, communications center, and airport police.

For more information, visit www.cleartronic.com

Let us hear your thoughts: Cleartronic, Inc. Message Board

Governments and insurance companies around the world are seeking innovative technologies that address the needs of the growing diabetic population in over-burdened public and private healthcare systems. In the U.S. alone, the national cost of diabetes in 2012 was $245 billion, compared to $174 billion in 2007.

LabStyle Innovations (OTCQB:DRIO) is answering this call with a preventative approach that reduces the cost of care while improving treatment and patient compliance. The company’s Dario™ Diabetes Management Solution is designed to help people with diabetes manage their disease with tools, insights and support via mobile phone.

The Dario™ all-in-one glucose monitoring solution includes a glucose meter, disposable test strip cartridge, and lancing device – all in a compact design that can fit into a pocket. The meter plugs into a smartphone device to automatically log and track blood sugar levels to provide actionable insights and alerts. Data is uploaded into a secure cloud database for diabetes-related clinical trials.

The platform’s web interface simplifies data sharing and progress, enabling easy and effective data management and ensuring patient compliance and improved quality of care. The Caregiver portal is being developed in order to assist caregivers to monitor their patients quickly and easily as well as enable more effective intervention as necessary – ultimately reducing costs.

Bottom line, Dario offers a preventative approach that reduces the costs of care, improves treatment, helps to prevent complications and facilitates patient compliance.

In April, LabStyle announced the initial stages of its global rollout of the Dario Diabetes Management System. The company’s goal is to “transform the daily management of diabetes” targeting the world’s more than 382 million people living with diabetes – a statistic expected to nearly double to 592 million by 2035.

Dario has already received regulatory approval in Europe, and U.S. FDA approval is expected later this year. The U.S. Patent and Trademark Office granted LabStyle a patent covering core functions of the Dario, and the company is pursuing patent applications in additional countries. Dario is currently available in the United Kingdom, New Zealand, Netherlands and Australia, and LabStyle plans to launch the solution in Canada and Italy this year as well.

The Israel-based company participates alongside bigger players addressing the global diabetes care market, including DexCom, Inc. (NASDAQ:DXCM), which develops and markets glucose monitoring products for adults and pediatric patients. Even Apple, Inc. (NASDAQ:AAPL) has jumped into the glucose monitoring market with an Apple Watch app developed by DexCom.

In terms of sales, the diabetes market is dominated by drug makers Novo Nordisk (NYSE:NVO), Sanofi (NYSE:SNY), and Merck (NYSE:MRK), in that order, according to data analytics firm GlobalData. The same report shows the Top 10 diabetes drugmakers, which also includes Pfizer (NYSE:PFE) and Eli Lilly (NYSE:LLY), made $62 billion in combined global sales last year, up more than 5 percent from the year prior.

If the crowded market and increasing number of diabetics worldwide is any inclination, LabStyle is in an opportunistic position to take its share of a rapidly growing market in need of innovative, cost-saving technologies and solutions.

For more information, visit www.mydario.com

Today, Galenfeha announced on its website that the company has brought on Chris W. Watkins as Senior Business Development Manager in its sales department. He joined Galenfeha on June 15, 2015.

Mr. Watkins adds nearly three decades of sales and management experience in the oil and gas industry, including directing sales operations and managing distributors throughout the Midwest and Rocky Mountain regions. Most recently, Mr. Watkins served as an Asia/Asia Pacific sales director, responsible for establishing international distribution channels, training distributors, and promoting product lines.

This news closely follows Galenfeha’s recent agreement with BHP Billiton (NYSE: BHP), in which Galenfeha will provide the U.S. oil and gas producer with advanced stored energy solutions. The move immediately broadens Galenfeha’s penetration in the oil and gas industry, and supports the company’s efforts to rapidly become a premier alternative stored energy supplier in North America, where it can further leverage its line of patent pending, microprocessor controlled, LiFePO4 chemistry battery systems for measurement, automation, and a full line of proprietary chemical injection systems.

For more information, visit www.galenfeha.com

Let us hear your thoughts: Galenfeha, Inc. Message Board

Consorteum Holdings is taking center stage in the emerging market of mobile gaming through the continued development of its proprietary Universal Mobile Interface (UMI). This groundbreaking technology will open the door for significant savings during game development by creating a carrier, operating system and device agnostic platform upon which to build. The company’s system eliminates the need for constant reprograming to keep up with operating system updates, providing potentially significant savings throughout the expensive app development process.

Initially, Consorteum intends to introduce its UMI technology in the mobile sports betting and casino gaming verticals. This strategy could provide the company with the opportunity to realize sustainable growth moving forward. According to a report by Super Data Research, the mobile platform continued to drive consumer growth in 2013, with the social casino games market accounting for combined revenue of approximately $2.9 billion in 2013. In 2015, the research firm forecasts total spending of approximately $4.4 billion across all platforms.

The company’s UMI is in a particularly strong position to expand within the mobile gaming industry as a result of its industry-leading dedication to compliance gaming. As the first and only third party developer approved for compliance gaming by the Nevada Gaming Commission, Consorteum will look to leverage its compliance-based features – including secure geo-fencing and geo-location requirements – in order to expand its market share in the future.

For Consorteum, potential applications within the mobile gaming industry are nearly limitless. From mobile lottery and sports book betting to slot machines and blackjack, the company’s proprietary technology puts it in a strong position to serve a collection of potential clients. Additionally, the company’s management team has highlighted a myriad of additional opportunities for growth within other industries and market sectors – including government, healthcare and banking applications.

Consorteum’s continued progress with its UMI technology makes the company an intriguing investment opportunity moving forward. When fully commercialized, the universal content delivery solution could prove to be a formidable platform for sustainable returns in the months that follow.

To learn more about Consorteum Holdings, visit www.consorteum.com

Let us hear your thoughts: Consorteum Holdings, Inc. Message Board

Today, the Aristocrat Group Corp. issued a press release to detail its latest distilled spirit offering, Big Box Vodka. The company’s intent is to create a new market segment by delivering an ultra-premium vodka in revolutionary packaging more versatile than anything else on the market today.

“This is not simply vodka in a cardboard box,” said ASCC CEO Robert Federowicz. “This is a handcrafted distilled spirit that arrives in a package that is more convenient and sophisticated than any bottle.”

Each Big Box Vodka package holds 1.75 liters, which is the equivalent of approximately 2 and a half 750 ml bottles. Also, the microflute cardboard is used provides superior durability and insulation. For superior convenience, every box contains a spouted, inner beverage bladder that can be removed for faster cooling times. In fact, consumers can pour ice directly on top of the beverage bladder, eliminating the need for ice buckets or coolers.

“This product was truly designed to go anywhere, from a public beach to a private yacht,” Federowicz said.

According to today’s press release, plans are calling for Big Box Vodka to be debuted at retail outlets in California, Nevada, Florida, Louisiana and Texas simultaneously this summer, representing a huge population of more than 90 million people. The company’s flagship brand, RWB Ultra-Premium Handcrafted Vodka, is already available online and at many bars and retailers.

For more information, visit www.aristocratgroupcorp.com/investors

Let us hear your thoughts: The Aristocrat Group Corp. Message Board

Integrated Environmental Technologies, Ltd. is a life sciences company focused on providing smart solutions to America’s most pressing environmental and health problems. Under the EcoTreatments™ brand, the company markets and sells Excelyte™, an anolyte disinfecting solution, and Catholyte Zero™, a proprietary cleaning solution. Excelyte is an EPA-registered hard surface disinfectant and sanitizer approved for use in hospitals and as a biocide in oil and gas drilling, while Catholyte Zero is an environmentally-friendly cleanser and degreaser for janitorial, sanitation and food processing purposes.

In recent months, the company has primarily focused on the distribution of its Excelyte solutions to oil and gas production clients. As of IEVM’s latest update in May, the company was providing its powerful disinfectant to four customers with 174 oil wells in the Uinta Basin of Utah and the Permian Basin of New Mexico. Moving forward, this progress will give IEVM a strong strategic advantage in expanding its presence among the estimated 30,000 oil producing wells distributed throughout the two regions.

“We continue to progress in the development of our oil and gas business and are currently in discussions with approximately five new customers interested in utilizing Excelyte to treat both oil and gas wells,” David R. LaVance, president and chief executive officer of IEVM, stated in a news release. “As expected, our growing industry footprint has enhanced our ability to cultivate and accelerate additional customers as we can provide hard data on the effects and the potential cost savings of Excelyte well maintenance treatments.”

According to the company’s data, Excelyte reduces the level of hydrogen sulfide gas in oil wells faster than any other well maintenance treatments. Hydrogen sulfide, a naturally occurring gas commonly released during oil and gas production, is the leading killer of oil field workers, demonstrating the tremendous potential benefits of the company’s solution. In addition to eliminating the dangerous gas, Excelyte is unique in that it leaves no environmental trace.

“Our product persists for only 90 days and then it disintegrates,” continued LaVance. “It’s not underground for very long and things go back to normal after that, so it’s a quick-acting biocide.”

By taking an environmentally-friendly approach to disinfecting solutions, IEVM is addressing many of the concerns associated with the fracking industry. According to a report by Forbes, a single fracking project uses millions of gallons of water and only 25 percent of that water is typically recovered for reuse. IEVM claims that by replacing toxic chemicals with the bacteria and sulfur-fighting properties present in Excelyte, the industry will be able to recover twice as much wastewater for reuse in fracking, limiting the need for additional fresh water.

Moving forward, IEVM will look to expand upon its growing network of customers in the oil and gas drilling industry. For prospective shareholders, the company’s developing presence in one of the world’s most vital market sectors makes it an intriguing investment opportunity in the months to come.

For more information, visit www.ecotreatments.com

Alternet Systems, Inc. (OTCQB: ALYI) is an enterprise accelerator company focused on the high growth, emerging technology fields of mobile payments and digital currency. Through its subsidiaries, the company is leveraging the extraordinary growth opportunities surrounding the explosion of newly adapted internet technologies and platforms to promote maximized returns for its shareholders.

In recent months, Alternet has placed much of its attention on the burgeoning digital currency market. In October, the company partnered with Wildcard Consulting, Inc. to launch the first U.S.-based bitcoin debit card. Designed to operate in full compliance with federal banking guidelines, this new product allows vendors to do business with consumers spending digital currencies while being paid accurately and securely in U.S. dollars or any other currency.

“Access to digital currency via a debit or credit card is a key step in the evolution of bitcoin and its integration with fiat currencies such as the U.S. dollar,” Henryk Dabrowski, chief executive officer of Alternet, stated in a news release. “We believe the time has come for holders of bitcoin to be able to exchange their digital currency for other assets seamlessly.”

In an effort to expand upon the seamlessness of digital currency payments, Alternet, through its Alternet Payment Solutions (APS) subsidiary, secured a strategic agreement with BitPay, the world leader in business solutions for the bitcoin digital currency industry. Through this agreement, the company is able to provide business to business payment methods through the conversion of fiat currency to digital currency in North America, South America and Asia. This partnership should continue to provide Alternet with a strong platform to build upon its recent growth moving forward.

The company is making additional progress on the digital currency front through the continued development of wholly-owned subsidiary OneMarket. When complete, OneMarket will become a fully-functioning digital currency exchange, offering an entire suite of financial and payment products targeting the growing digital currency market. In the coming months, Alternet will continue to aggressively pursue the highly anticipated New York State BitLicense, which will be necessary to facilitate the company’s global exchange strategy.

“It is our intent to continue pursuing a strategy of cooperation with regulators so that when we are granted permission we have put all the necessary building blocks in place to take the maximum advantage of our ability to monetize,” continued Dabrowski.

For more information, visit www.alternetsystems.com